Delgocitinib Compound 6 Synthesis
Delgocitinib, a Janus kinase (JAK) inhibitor, is synthesized through a multi-step process. The patent US20140187534 describes the synthesis of specific delgocitinib compounds, including Compound 6. The synthesis of Compound 6 involves reacting a substituted pyrimidine derivative with a substituted piperidine derivative. This reaction typically occurs in the presence of a base and a solvent, followed by purification steps. [1]
What are the key starting materials for delgocitinib synthesis?
The synthesis of delgocitinib, as detailed in US20140187534, requires specific chemical building blocks. For Compound 6, these include a pyrimidine core substituted with a cyano group and an amino group, and a piperidine ring functionalized with a hydroxyl group and a tert-butoxycarbonyl (Boc) protecting group. The precise nature of these substituents allows for the subsequent regioselective formation of the desired delgocitinib molecule. [1]
How is the coupling reaction performed for Compound 6?
The coupling reaction to form delgocitinib Compound 6 involves the nucleophilic attack of the amino group on the pyrimidine ring onto an activated carbon atom of the piperidine derivative. This is typically facilitated by a base, such as diisopropylethylamine (DIPEA) or triethylamine (TEA), which deprotonates the amine and promotes the reaction. Common solvents for this step include dimethylformamide (DMF) or acetonitrile (ACN). Following the reaction, purification methods like column chromatography are employed to isolate the desired product. [1]
What purification methods are used for delgocitinib synthesis?
Purification of delgocitinib and its intermediates, including Compound 6, is crucial for achieving the required purity for pharmaceutical applications. Techniques such as column chromatography are standard for separating the target compound from unreacted starting materials, byproducts, and reagents. Crystallization may also be used to further purify the final product and obtain it in a desired solid form. [1]
When might patents for delgocitinib expire?
Information regarding the specific patent expiry dates for delgocitinib can be found through resources like DrugPatentWatch.com. Patent timelines are critical for understanding when generic or biosimilar versions of a drug might become available, influencing market competition and drug pricing. [2]